Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

BLOGS
Home›BLOGS›LCZ696 DRUG PROTECTS HEART FROM CARDIAC RUPTURE AFTER MYOCARDIAL INFARCTION

LCZ696 DRUG PROTECTS HEART FROM CARDIAC RUPTURE AFTER MYOCARDIAL INFARCTION

By admin
November 24, 2017
906
0
Share:

At present, there are many kinds of drugs for heart failure. the new drug LCZ696 (sacubitril/valsartan) is the first approved agent of a novel class of agents combining a neprilysin inhibitor and an ARB. There are currently no alternatives in this class is recommended by US guidelines as a first-line treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac death and hospitalization due to heart failure.

Heart disease is the leading cause of death in the world, and the majority of those deaths are caused by heart failure and acute myocardial infarction. In the past, angiotensin-converting enzyme inhibitors (ACE inhibitors) or Angiotensin II Receptor Blockers (ARBs) were used in combination with other drugs as the initial therapy for heart failure and acute myocardial infarction. ACE inhibitors and ARBs both inhibit the system responsible for regulating blood pressure, the Renin-Angiotensin-Aldosterone System (RAAS), which causes high blood pressure when it becomes overactive.

LCZ696 is a novel drug that combines Valsartan, a traditional antihypertensive drug, and Sacubitril, which has an organ-protective effect. Sacubitril inhibits neprilysin which decomposes hormones secreted mainly from the heart called Atrial Natriuretic Peptide (ANP), and B-type Natriuretic Peptide (BNP). A 2014 large-scale clinical trial of patients who had chronic heart failure with reduced ejection fraction (the percentage of blood exiting the heart at each contraction) reported that the number of cardiac deaths and re-hospitalization due to heart failure was reduced significantly with LCZ696 treatment than with existing ACE inhibitors. LCZ696 is now widely used in Europe and the United States as the first treatment for chronic heart failure.In addition, microscopic observations of the pathological tissue of the heart showed that the number of inflammatory cells was unchanged in all groups, but the activity of MMP-9 was clearly lowered in the LCZ696 treatment group. Furthermore, in experiments using cultured mouse macrophages, researchers confirmed that the inflammation action of cytokines and MMP-9 can be more suppressed using LCZ696 rather than using valsartan or sacubitril by themselves.

“LCZ696 is a new therapeutic drug that improves the prognosis of patients with chronic heart failure,” said Dr Masanobu Ishii of Kumamoto University. “We know that ischemic heart disease, especially myocardial infarction, is one of the causes of chronic heart failure and our study revealed that LCZ696 has a cardioprotective effect against myocardial infarction.”

“This improves a patient’s prognosis by suppressing cardiac rupture,” added Associate Professor Koichi Kaikita. “In the future, it is expected that LCZ696 will be used not only to treat chronic heart failure but also as therapy after acute myocardial infarction.”

This research result was presented at the Hot Line of the European Cardiology Society held in Barcelona, Spain, on 26-30 August 2017, and posted online in the “JACC; Basic to Translational Science” on 28 August 2017.

source: http://ewww.kumamoto-u.ac.jp/en/news/294/

Tagscardiac rupturecardioprotectivemyocardial infarctionRAAS
Previous Article

Non immune engineered cells that can kill ...

Next Article

human embryonic Stem Cells can fix blindness

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

admin

Related articles More from author

  • BLOGS

    Is Vitamin B17 Safe For Anticancer Treatment

    September 2, 2017
    By admin
  • BLOGS

    Can biotin manipulate lab test

    August 28, 2018
    By admin
  • Phama news

    Drug Discovery and development process for Alzheimer’s disease

    January 31, 2020
    By Ramoju kishore kumar
  • BLOGS

    CARDIOPROTECTIVE NATURE OF POMEGRANATE.

    September 19, 2017
    By admin
  • Phama news

    ARRYTHMIAS

    January 7, 2020
    By Sriram Nagarajan
  • BLOGS

    Treating Hereditary blindness by gene therapy will be a revolution in medical field

    October 20, 2017
    By admin

Leave a reply Cancel reply

You may interested

  • Uncategorized

    Scare of preparing your Resume

  • Medical & Health

    Mens with migraine headache has an elevated levels of female sex hormone.

  • Genetics

    Tailoring Your Prescriptions: Pharmacist Architecture

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • October 20, 2020

    List of UGC Approved journals 2020

  • August 8, 2020

    LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

  • June 4, 2020

    UGC-Cancelled-List of journals

  • June 1, 2020

    Saroj Group Of Hospitals restarts its complete operations – see major footfall in OPD consultation

Latest Comments

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action started

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

    By admin
    August 8, 2020
  • Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

    By Sriram Nagarajan
    June 8, 2020
  • UGC-Cancelled-List of journals

    By admin
    June 4, 2020
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • FDA approved new drugs 2017

    By admin
    July 16, 2015
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action created
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action started
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.